Answers are grounded in this paper and cite their sources.
The relationship between microsatellite instability (MSI) - high (H) and deficient DNA mismatch repair is, in fact, not straightforward. MSI observed in genome-edited cells carrying Lynch syndrome mutations is not so drastic as in typical MSI-H ( i.e. Type B mode) but uniformly more subtle ( i.e. Type A mode). In our preceding study, we demonstrated a tight connection between the more subtle mode of MSI, i.e. Type A MSI, and 5-FU resistance in colorectal cancer patients. In this study, we tested if Type A MSI is similarly useful to predict tumour sensitivity to immune checkpoint inhibitors (ICIs). In thirty-eight gastric cancer patients treated with nivolumab monotherapy, eleven ‘good responders’ and eight ‘poor responders’ were selected according to iRECIST and enrolled. In them, Type A MSI was indeed observed, and seven patients were judged as Type A-positive. More importantly, Type A MSI was significantly more frequent in ‘good responders’ than in ‘poor responders’ (7/11 vs 0/8, p = 0.013). Our findings in this pilot cohort may shed light on the potential utility of more subtle Type A MSI to predict response to ICIs in cancer patients.
No takes yet. Share an insight, caveat, or question.
Miyashita et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: